← Back
$ZBIO All transactions

Zenas BioPharma, Inc.

▲ BUY
6 / 10

Conviction

$ Value

$1000K

Shares

58,823

Price

$17

Filed

Oct 9

Why this score? (6/10)
  • Open market buy (+3)
  • Trade value >= $250K (+1)
  • Director (+1)
  • Not a 10b5-1 plan (+1)

Insider

Name

Lu Hongbo

Title

CIK

0001767584

Roles

Director

Transaction Details

Transaction Date

2024-09-13

Code

P

Table

Non-Derivative

Ownership

Indirect

Equity Swap

No

Shares After

58,823

Footnotes

The reported securities are owned directly by NEXTBio Master Fund LP and may be deemed to be indirectly beneficially owned by (i) NEXTBio Capital LLC, the general partner of NEXTBio Master Fund LP, (ii) NEXTBio Capital Management LP, the investment manager to NEXTBio Master Fund LP, and (iii) Hongbo Lu, a managing member of NEXTBio Capital LLC. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. | The reported securities are owned directly by NEXTBio Master Fund LP or NextBio Evergreen LLC and may be deemed to be indirectly beneficially owned by (i) NEXTBio Capital LLC, the general partner of NEXTBio Master Fund LP (with respect to such securities directly owned by NEXTBio Master Fund LP), (ii) NEXTBio Capital Evergreen GP LLC, the managing member of NEXTBio Evergreen LLC (with respect to such securities directly owned by NextBio Evergreen LLC), (iii) NEXTBio Capital Management LP, the investment manager to NEXTBio Master Fund LP and NextBio Evergreen LLC, and (iv) Hongbo Lu, a managing member of NEXTBio Capital LLC and NEXTBio Capital Evergreen GP LLC. | (Continued from footnote 2) The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Filing Info

Accession No.

0000919574-25-006031

Form Type

4

Issuer CIK

0001953926

Lu Hongbo's History

Date Ticker Type Value
2026-03-31 ZBIO $1.5M
2026-03-31 ZBIO $70K
2025-12-16 ARWR A $0
2025-10-07 ZBIO $5.0M
2025-06-11 TERN A $0
2025-06-10 ZBIO A $0
2024-09-13 ZBIO $1000K

Other Insiders at ZBIO (90d)

Insider Bought Sold Last
Fairmount Funds Management LLC $3.0M 2026-03-31
Lu Hongbo $1.6M 2026-03-31
MOULDER LEON O JR
Chief Executive Officer
$1.0M 2026-03-31